高级检索
    吴雨微, 赵明芳, 柯娥娥. CASPIAN研究: Durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益[J]. 循证医学, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007
    引用本文: 吴雨微, 赵明芳, 柯娥娥. CASPIAN研究: Durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益[J]. 循证医学, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007
    shu
    WU Yu-wei, ZHAO Min-fang, KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007
    Citation: WU Yu-wei, ZHAO Min-fang, KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007
    shu

    CASPIAN研究: Durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益

    Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial

      摘要
      • HTML全文
      • 参考文献(6)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回